Loading...
Loading...
EPIX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 24.0K |
| Gross Profit | -24.0K |
| Operating Expense | 7,357.6K |
| Operating I/L | -7,381.7K |
| Other Income/Expense | 1,006.9K |
| Interest Income | 1,008.8K |
| Pretax | -6,374.8K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -6,374.8K |
ESSA Pharma Inc. is a clinical stage pharmaceutical company specializing in developing novel therapies for prostate cancer treatment. Its primary focus is on the development of EPI-7386, an oral candidate currently in Phase I clinical study for metastatic castration-resistant prostate cancer. The company generates revenue through collaboration agreements with industry leaders such as Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc., leveraging its expertise and proprietary therapies to advance the treatment of prostate cancer.
